comparemela.com

Latest Breaking News On - Geoffrey barnes - Page 20 : comparemela.com

Doctors say blood clots appear to be extremely rare for Johnson & Johnson vaccine recipients

The Mississippi State Department of Health is telling physicians, clinics and hospitals to stop using the Johnson & Johnson COVID-19 vaccine until further guidance is issued by the CDC and the FDA.

EXPLAINER: What s known about COVID vaccines and rare clots

A rare, rogue immune response is the main suspect as authorities investigate highly unusual blood clots following use of two similar COVID-19 vaccines from Johnson & Johnson and AstraZeneca. The U.S. recommended that states pause giving the J&J vaccine on Tuesday while authorities examine six reports of the unusual clots, including a death, out of more than 6.8 million Americans given the one-dose vaccination so far. Also Tuesday, J&J delayed its imminent European rollout.

Johnson & Johnson pause has similarities to AstraZeneca, not Pfizer or Moderna vaccines

Johnson & Johnson pause has similarities to AstraZeneca, not Pfizer or Moderna vaccines Updated 2:33 PM; Today 1:52 PM Rashanna Snorden administers the Johnson and Johnson Covid-19 vaccine to a community member during Detroit Health Department s Neighborhood Vaccine Week at Western International High School on Monday, April 12, 2021 in Detroit. Nicole Hester/ MLive.com Facebook Share Federal regulators recommended halting the use of Johnson & Johnson’s COVID-19 vaccine in the U.S. after a handful of rare but serious adverse reactions involving blood clotting were reported earlier this week. In number, the cases aren’t statistically significant. There are six known cases to date out of more than 6.8 million doses of the single-dose vaccine administered across the country.

US recommends pause for J&J shots in blow to vaccine drive

WASHINGTON (AP) — The U.S. on Tuesday recommended a “pause” in use of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of rare but potentially dangerous blood clots, setting off a chain reaction worldwide and dealing a setback to the global vaccination campaign. The Centers for Disease Control and Prevention and the Food and Drug Administration announced that they were investigating unusual clots in six women between the ages of 18 and 48. One person died. The acting FDA commissioner expected the pause to last only a matter of days. But the decision triggered swift action in Europe and elsewhere as the drugmaker and regulators moved to halt the use of the J&J vaccine, at least for now. Hundreds of thousands of doses were due to arrive in European countries, where vaccinations have been plagued by supply shortages, logistical problems and concerns over blood clots in a small number of people who received the AstraZeneca vaccine, which is not y

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.